No approved treatment has been able to halt the underlying disease processes in the brain in AD patients, and no new treatment has been approved at all in the last decade in this field.Research, and the development of new therapies, has been fraught by a large number of late-stage, high-profile failures in recent years and a vast number of asset suspensions in the earlier stages of development, too.
According to data held by BioMedTracker (BMT), the AD pipeline in the US includes 47 Phase I products that have...
Welcome to Scrip
Create an account to read this article
Already a subscriber?